SHANGHAI – Neostem Inc. signed an exclusive license agreement with Cellular Biomedicine Group, of Shanghai, for its patient-specific immunotherapy (DC-TC) to treat late-stage hepatocellular carcinoma (HCC) in China, home to more than 45 percent of the world's HCC patients.